Oculis Holding AG (OCS)

Market Cap	1.46B
Revenue (ttm)	991,999
Net Income (ttm)	-130.55M
Shares Out	57.81M
EPS (ttm)	-2.67
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	428,482
Open	23.82
Previous Close	23.84
Day's Range	23.61 - 26.17
52-Week Range	14.00 - 26.17
Beta	0.14
Analysts	Strong Buy
Price Target	39.57 (+56.9%)
Earnings Date	Nov 10, 2025

About OCS

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases in Switzerland, Iceland, and internationally. The company’s lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2003
• Employees: 49
• Stock Exchange: NASDAQ
• Ticker Symbol: OCS
• Website: https://oculis.com

Financial Performance

In 2024, Oculis Holding AG's revenue was 686,000, a decrease of -22.31% compared to the previous year's 883,000. Losses were -85.78 million, -3.41% less than in 2023.

Financial numbers in CHF

Analyst Summary

According to 7 analysts, the average rating for OCS stock is "Strong Buy." The 12-month stock price target is $39.57, which is an increase of 56.90% from the latest price.

Price Target

$39.57

(56.90% upside)

Analyst Consensus: Strong Buy